Emerging Trends Influencing The Growth Of The Non-Alcoholic Steatohepatitis Biomarkers Market:Advancements In Nis4 Technology Pave The Way For Innovative Blood-Based Molecular Diagnostic Test

The Non-Alcoholic Steatohepatitis Biomarkers Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Non-Alcoholic Steatohepatitis Biomarkers Market?
There has been a substantial expansion in the market size for non-alcoholic steatohepatitis biomarkers in recent times. The market is projected to expand from its current value of $1.36 billion in 2024 to approximately $1.7 billion in 2025, marking a compound annual growth rate (CAGR) of 24.8%. The historic period's upturn can be associated with elements such as diabetes and metabolic syndrome, awareness and screening initiatives, limitations of liver biopsy, regulatory backing, the trend towards personalized medicine, and clinical trials in NASH.

In the coming years, the non-alcoholic steatohepatitis biomarkers market is projected to undergo significant expansion. The projected size of the market by 2029 is around $3.86 billion with a compound annual growth rate (CAGR) of 22.8%. This anticipated growth within the forecast period is due to several factors including the advent of new therapies, the advancement of precision medicine, patient advocacy efforts, the consolidation of multi-omics data and improved patient engagement strategies. Key market trends for the forecast period encompass telemedicine and remote patient monitoring, cutting-edge diagnostic platforms, international research collaborations, breakthroughs in biomarker discovery technology, the integration of artificial intelligence (AI), and the incorporation of imaging biomarkers.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9002

What Are the Emerging Segments Within the Non-Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented -

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

What Long-Term Drivers Are Shaping Non-Alcoholic Steatohepatitis Biomarkers Market Trends?
The surge in liver cancer incidences is anticipated to fuel the expansion of the non-alcoholic steatohepatitis biomarkers market in the coming years. Liver cancer is marked by the emergence of malignant tumors within the liver, originating either from the liver itself, termed as primary liver cancer or from elsewhere, ending up in the liver, known as secondary or metastatic liver cancer. Biomarkers for non-alcoholic steatohepatitis (NASH) are employed in liver cancer for early diagnosis, tracking disease progression, evaluating treatment responses, offering predictive data, and potentially lowering the dependence on invasive procedures. For example, the World Cancer Research Fund, a not-for-profit organization based in the UK, reported in 2022 that globally around 866,136 new liver cancer cases emerged, positioning liver cancer as the 6th most prevalent cancer in the world. Hence, the increasing incidences of liver cancer are boosting the growth of the non-alcoholic steatohepatitis biomarkers market.

Who Are the Top Competitors in Key Non-Alcoholic Steatohepatitis Biomarkers Market Segments?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

What Non-Alcoholic Steatohepatitis Biomarkers Market Trends Are Gaining Traction Across Different Segments?
Innovations in technology are a major trend driving the non-alcoholic steatohepatitis biomarkers market forward. Key players in the market are dedicating resources to introduce new solutions that enhance their standing in the market. In an instance from October 2022, GENFIT, a late-stage biopharmaceutical company from France, and LabCorp, a life sciences company from the US, settled on an exclusive five-year licensing agreement for GENFIT's NIS4 technology to help identify NASH-at-risk patients. The NIS4 technology is a revolutionary multi-biomarker-based algorithm created to detect patients with non-alcoholic steatohepatitis (NASH) and considerable to severe fibrosis (F > 2), also known as at-risk NASH. LabCorp, as part of the agreement, will create and market a blood-based molecular diagnostic test that applies NIS4 technology within the US and Canada, providing extensive accessibility to healthcare professionals.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Which Regions Are Becoming Hubs for Non-Alcoholic Steatohepatitis Biomarkers Market Innovation?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Non-Alcoholic Steatohepatitis Biomarkers Market?
2. What is the CAGR expected in the Non-Alcoholic Steatohepatitis Biomarkers Market?
3. What Are the Key Innovations Transforming the Non-Alcoholic Steatohepatitis Biomarkers Industry?
4. Which Region Is Leading the Non-Alcoholic Steatohepatitis Biomarkers Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.